Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

Panisset M, Gauthier S, Moessler H, Windisch M

Journal of neural transmission (Vienna, Austria : 1996)1 Jul 2002Cited by 32 (Europe PMC)

PMID12111446DOI10.1007/s007020200092PepBankPUB-12111446

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialSafety outcome
In Alzheimer's disease patients, adverse events occurred in 64% with Cerebrolysin and 73% with placebo.
In plain wordsIn Alzheimer's disease patients, adverse events occurred in 64% with Cerebrolysin and 73% with placebo.
Peptide
Cerebrolysin
Outcome
DecreaseAdverse events
Study
n = 192
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Measurements
Adverse events
64%
Cere
Adverse events
73%
placebo
Source sentences
Summary
Adverse events were recorded in 73% of placebo and 64% of Cere patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Report a problemFND-1211144605
02HumanRandomized controlled trialSafety outcome
In the Alzheimer's disease Cerebrolysin trial, the most common adverse events were headaches, dizziness, weight loss and anxiety, without arm-specific attribution.
In plain wordsIn the Cerebrolysin Alzheimer's trial, headaches, dizziness, weight loss and anxiety were the most common adverse events. The summary did not identify their groups.
Peptide
Cerebrolysin
Outcome
Direction not reportedMost common adverse events (headaches, dizziness, weight loss, anxiety)
Study
n = 192
Outcome group
Adverse events · Nervous system and cognition
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Source sentences
Summary
Most common adverse events were headaches, dizziness, weight loss and anxiety.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Report a problemFND-1211144606
03HumanRandomized controlled trialEfficacy outcome
In Alzheimer's disease patients, Cerebrolysin improved CIBIC+ versus placebo at week 12.
In plain wordsIn Alzheimer's disease patients, Cerebrolysin improved global function more than placebo at week 12.
Peptide
Cerebrolysin
Outcome
IncreaseCIBIC+ at week 12
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Measurements
P value for CIBIC+ at week 12
0.033
Cere versus placebo at week 12
Source sentences
Summary
At week 12 there was a significant difference on the CIBIC+ (p = 0.033) in favor of Cere.
2 context sentences(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Summary · context
192 patients were enrolled, 95 were randomized to placebo, and 97 to Cere.
Report a problemFND-1211144601
04HumanRandomized controlled trialEfficacy outcome
In Alzheimer's disease patients, CIBIC+ response was higher with Cerebrolysin than placebo, at 76% versus 57%.
In plain wordsIn Alzheimer's disease patients, global response was higher with Cerebrolysin than placebo, at 76% versus 57%.
Peptide
Cerebrolysin
Outcome
IncreaseCIBIC+ responders
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Measurements
Responders
68 patients
Cere
Responders
51 patients
placebo
Response rate
76%
Cere
Response rate
57%
placebo
P value for CIBIC+ responder comparison
0.007
CIBIC+ responders in the Cere group versus the placebo group
Source sentences
Summary
The number of CIBIC+ responders (score < or = 4), was significantly higher (p = 0.007), with 68 (76%) in the Cere group and 51 (57%) in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Summary · context
192 patients were enrolled, 95 were randomized to placebo, and 97 to Cere.
Report a problemFND-1211144602
05HumanRandomized controlled trialEfficacy outcome
In Alzheimer's disease patients, the Cerebrolysin trial reported a trend on the Disability Assessment in Dementia scale without specifying its direction.
In plain wordsIn Alzheimer's disease patients, the Cerebrolysin trial reported a disability-score trend but did not specify its direction.
Peptide
Cerebrolysin
Outcome
Direction not reportedDisability Assessment in Dementia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Source sentences
Summary
Trends were noted in the Disability Assessment in Dementia scale and the Cornell Depression Scale.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Report a problemFND-1211144603
06HumanRandomized controlled trialEfficacy outcome
In Alzheimer's disease patients, the Cerebrolysin trial reported a Cornell Depression Scale trend without specifying its direction.
In plain wordsIn Alzheimer's disease patients, the Cerebrolysin trial reported a depression-score trend but did not specify its direction.
Peptide
Cerebrolysin
Outcome
Direction not reportedCornell Depression Scale
Study
n: not reported in source
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
30 mL · intravenous · four weeksAs given in this study (human).
Source sentences
Summary
Trends were noted in the Disability Assessment in Dementia scale and the Cornell Depression Scale.
1 context sentence(design, population, supporting numbers)
Summary · context
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks.
Report a problemFND-1211144604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase 4NCT01822951

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)

Ever Neuro Pharma GmbHn = 0Completion est. Dec 2016

Alzheimer Disease

Trial page ClinicalTrials.govUpdated 26 Oct 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.